Good afternoon everyone. My name is Liza and I will be your conference operator today. I would like to welcome everyone to the Halozyme Fourth Quarter and Full-Year 2021 Financial Results Conference Call. All lines have been muted to prevent background noise. After the speakers' remarks, there will be a question-and-answer session. I would like to hand things over to Mr. Al Kildani. Please go ahead, sir.

Good afternoon and welcome to our fourth quarter and full-year 2021 financial results conference call. In addition to our press release issued today after the close, you can find a supplementary slide presentation that will be referenced during today’s call in the Investor Relations section of our website. Leading the call will be Dr. Helen Torley, Halozyme’s President and Chief Executive Officer, who will provide an update on our business; and Nicole LaBrosse, our new Chief Financial Officer, who will review our financial results for the fourth quarter. On today’s call, both GAAP and non-GAAP financial measures will be discussed. The non-GAAP or adjusted financial measures are reconciled with comparable GAAP financial measures in our earnings press release and slide presentation. During the call, we will be making forward-looking statements. I refer you to our SEC filings for a full listing of the risks and uncertainties. I’ll now turn the call over to our CEO, Helen Torley.

Thank you, Al. I'm pleased to welcome Nicole to the call and congratulate her on her new role as our Chief Financial Officer after doing such a terrific job as our VP of Finance and as our Controller. I’m going to begin today with a brief review of our record 2021 financial performance, which has created strong momentum entering 2022. Total revenues in 2021 grew 66% year-over-year to $443 million. Operating income grew 91% to $276 million and non-GAAP earnings per share for the year was $2. All of these measures are within the range of our final 2021 guidance. This strong 66% revenue growth was driven by royalty revenue growth of 130% year-over-year, a $40 million upfront milestone payment for the signing of our eleventh enhanced collaboration agreement with ViiV Healthcare and additional development and commercial milestones associated with launch progress and the strong momentum in our development portfolio where we achieved our goal of 10 new partner study starts in 2021. This strong progress and results in revenue growth allowed us to continue to demonstrate our strong commitment to capital return through the completion of our $550 million share buyback plan, ahead of schedule in October of 2021 and announcement of a new three-year $760 million share repurchase program, inclusive of $160 million accelerated share repurchase program, which was initiated in December 2021. These achievements and the results of momentum have positioned us well for continued revenue and operating income growth in 2022 and beyond. In January, we provided our 2022 guidance. For full year 2022, we expect revenues of $530 million to $560 million, which represent growth of 20% to 26%, driven primarily by projected royalty revenue growth of approximately 50%. Also contributing to our revenue projection this year, we have included a new deal milestone payment in our guidance based on our expectation for a new agreement to be signed in 2022. Operating income is projected to be $350 million to $380 million showing robust growth of 27% to 38%. We expect non-GAAP earnings per share of $2.05 to $2.20, recalling that in 2022 we’re seeing the impact of our first year of tax expense which is projected at $0.55 to $0.60 per share. With that overview let me now provide some additional details beginning with the royalty revenue growth, starting with a summary of 2021 results shown on Slide 3. Royalties during the fourth quarter were $62.6 million. This represented 96% growth year-over-year and 7% sequential growth. This resulted in full-year 2021 revenues and royalties of $204 million, representing approximately 130% year-over-year growth from $89 million in 2020. Royalty revenue growth continues to be driven primarily by the successful ongoing global launches of Janssen’s subcutaneous forms of DARZALEX, which utilizes our enhanced technology. Based on the strong momentum of this high margin with current revenue stream, we predict continued royalty revenue growth in 2022, with growth of approximately 50% to approximately $300 million. Moving now to Slide 4, we have five commercialized products utilizing ENHANZE that are contributing to our royalty revenues. It's estimated that these products have been used to treat more than 600,000 patients globally. Our wave 2 products, Janssen’s DARZALEX subcut and Phesgo are the current royalty revenue growth drivers and have substantial growth opportunities ahead for each of them. Turning to Slide 5, I'll review DARZALEX. During its fourth quarter call, Janssen’s parent Johnson & Johnson reported the following strong fourth quarter sales, total DARZALEX sales in 2021, including both IV and subcu were $6 billion, an increase of 42.3% on an operational basis over 2020. J&J further stated that the fourth quarter growth was driven by a combination of share gains, increased penetration of the subcutaneous formulation in the U.S. and Europe, and continuing launches globally. Notably, DARZALEX’s share increased across all lines of therapy with nearly 8 points of share growth in the United States. Turning to DARZALEX FASPRO in the United States again during the quarter achieved a 76% share of total DARZALEX sales in the month of December, an increase from a 72% share of total sales at the end of September. We estimate that DARZALEX SC achieved an annualized share of approximately 58% of total DARZALEX sales in 2021. And we project continued strong DARZALEX SC growth and result in growth in our royalty revenues, driven by continued growth in the worldwide total DARZALEX sales, which are projected by analysts to increase to approximately $10 billion in 2025 and continued growth in the annualized subcutaneous share to notably higher than our current 58%. Beyond this strong commercialization and financial performance, key developments for the subcutaneous DARZALEX franchise redemption in the quarter included an FDA approval for DARZALEX FASPRO in combination with Kyprolis and dexamethasone, which was for patients with relapsed or refractory multiple myeloma who received one to three prior lines of therapy. This represented the ninth indication for which DARZALEX FASPRO has been approved in the United States. An approval was also received from the China National Medical Products Administration for the use of DARZALEX FASPRO for the treatment of newly diagnosed primary light chain amyloidosis. Moving now to our second of least two products and driver of royalty revenue growth, that’s Phesgo. In the fourth quarter, Roche reported fourth quarter Phase 2 sales of 127 million Swiss francs, up from 117 million Swiss francs in the third quarter. Phesgo sales for the year were 340 million Swiss francs. We continue to expect strong quarter-over-quarter growth of Phesgo as a result of the ongoing launches in Europe and the rest of the world following a team member reimbursement and continued penetration into oncology accounts in the United States. Let me move now to Slide 6 and a discussion of the ENHANZE development portfolio. It is our goal to continuously expand the number of products that are in development and to advance products to later stages of development and launch as in many cases, this is associated with milestone revenue payments to Halozyme. I'll begin with an overview of the ENHANZE partner product pipeline as of February 2022. I’m pleased to report that our ENHANZE partners initiated four new Phase 1 trials in the fourth quarter, each for a new product that resulted in an expansion of our development portfolio. Specifically, in December, we’ve initiated enrollment with a Phase 1 study to evaluate cabotegravir administered subcutaneously with ENHANZE and Janssen also initiated a Phase 1 clinical trial evaluating their small molecule rilpivirine with ENHANZE. In November, both initiated a Phase 1 study combining an undisclosed therapy and target with ENHANZE, and in October, Takeda initiated a Phase 1 study to assess the tolerability and safety of immune globulin subcutaneous 20% solution with ENHANZE. These new programs are reflected in the updated pipeline chart on Slide 6. With these four Phase 1 study initiations, we exceeded our goal of five new Phase 1 trial starts in 2021, achieving a total of six. We also achieved our goals to have three products in Phase 3 development and to expand the total number of programs in development. Looking ahead for 2022, we expect further pipeline progress and expansion with at least five new Phase 2 or 3 trial starts for existing ENHANZE partner programs and four new products utilizing ENHANZE to enter Phase 1 development by the end of 2022. Staying on Slide 6, let me now provide a brief update on the next set of potential launches, which we call our wave 3 launches. All of our wave 3 potential launch products are currently approved as IV drugs and are in Phase 3 development as a subcutaneous drug with ENHANZE. Based on historical development timelines, these represent potential launches in the 2023 to 2025 time frame, and include Bristol Myers Squibb’s nivolumab, Roche’s atezolizumab, and others. Analysts project that the total revenue potential for both the IV and subcutaneous formulations for this next set of our potential launches will exceed $20 billion in 2025. What will be key for Halozyme is the pace of conversion from IV to subcutaneous and the peak conversion share attained. Let me move to argenx's efgartigimod, which was approved in its IV form by the FDA in December of last year for the treatment of patients with myasthenia gravis. It is currently leading the race to become the first of our wave 3 product launches with the potential for approval in 2023. Moving to the subcutaneous development, argenx has integrated ENHANZE broadly in its strategy and vision for Efgartigimod with five Phase 3 studies for five distinct indications now ongoing. The most advanced SC Study is from myasthenia gravis. Excitingly, argenx now expects top-line data from its adapt SC study of efgartigimod with ENHANZE for myasthenia gravis in the first quarter of this year. Three additional top-line data readouts of SC are expected in the next 12 months or so, with data from the Pemphigus study in the fourth quarter of this year and from ITP and the CIDO studies in the first quarter of 2023. We're also pleased to add that in December, argenx initiated a trial of subcutaneous atezolizumab in patients, the fifth indication to be evaluated. The projected size of the addressable populations and the large unmet need that exists in each of these indications are resulting in analysts projecting a multi-billion dollar opportunity for efgartigimod. Moving now to additional wave 3 products, Roche’s atezolizumab and BMS’ nivolumab continue to progress in their Phase 3 studies evaluating SC delivery with ENHANZE, and these also have the potential for launch in the 2023 to 2025 timeframe. Now, I’ll move to the top of this slide or the products that are in completed Phase 1 development. We call these our wave 4 potential launch products, and we have the potential for launch in the 2025 to 2027 timeframe. Clearly, this pipeline represents a broad diverse and exciting set of opportunities. Today, I'll focus on highlighting a series of new studies in HIV or enhances this study in both small and large molecules. We're delighted that we’ve initiated a Phase 1 study of the HIV therapy Cabotegravir in combination with ENHANZE. These as previously indicated expects Phase 1 data from this study and from another study with ENHANZE, which will include their broadly neutralizing antibody N6LS in 2022. ViiV has been clearly moving at a rapid pace and we’re delighted to be supporting them in their mission for HIV patients. In addition, Janssen initiates the Phase 1 study of their small molecule products Rilpivirine with ENHANZE. This is the third target Janssen is now studying with ENHANZE. Finally, Janssen and ViiV together have indicated they plan to explore the possibility of an ultra-long acting version of CABENUVA using ENHANZE. CABENUVA is a co-packaged injectable medication for the treatment of HIV containing both Cabotegravir and Rilpivirine. Let me move now to Slide 7 and our pipeline progress to date really has been able to drive collaborative revenues for Halozyme, which are a key contributor to our cash flow and has enabled our commitment to capital return through share buyback. Over the last several years, we provided three-year guidance on milestone revenue, which is shown in the green bars. Representing the blue bars is our performance against that. I'll just make some key points here, firstly, our three-year milestone revenue predictions have increased over time with the maturing and the expansion of our portfolio. Secondly, we have met or exceeded our guidance in each of the periods. Please note that last month we updated our outlook for the two-year period of 2022 to 2024, during which we expect to increase milestones again to $450 million to $500 million in total milestones resulting from a mix of development, commercial, and new agreement milestones. Let me move now to the long-term outlook for the ENHANZE franchise. As we project forward to 2027, we continue to see the potential to achieve approximately $1 billion in royalty revenues based on wave 1 through 4 products, which are currently approved products, and the products that are projected to be in clinical development with ENHANZE by the end of 2022. I know this is a non-risk adjusted projection and does assume global launches in all indications. Looking even beyond 2027 to 2031, we see a clear path towards the potential for royalty revenues to exceed $1 billion. We're completing this out projection to date to help our investors better understand the drivers of revenue durability based on our knowledge of our programs, our plans, and also the confidence terms in our collaboration agreements. A continued growth potential post-2027 is driven by four factors. Firstly, the ongoing growth of the products that are creating the $1 billion potential, some of which will be launching in the 2020 segment timeframe and will be early in their growth cycle. Secondly, we project and expect there will be new product launches that are not reflected in the current financial projections and would represent our wave 5 launches. These new products will result from our current partners, but also new partners advancing additional subcutaneous products into development in late 2022 and beyond. The third factor is, it is expected that more co-formulation patents will be granted, which have the effect of extending the duration of time we receive royalties. As a reminder, we typically receive royalties for a minimum of 10 years after the first commercial sale. In addition, co-formulation patents can potentially allow the base royalty rates to remain unchanged for an extended period following the expiry of the base composition of the master patents. I am pleased to report that several partners recently filed new co-formulation patent applications related to products in the ENHANZE development pipeline. I move forward to being able to provide further updates on these applications as this information becomes public. Now the fourth factor is the potential for our current and new partners to utilize our new more extended room temperature stable rHuPH20, which has the potential to launch post 2027 and has IP coverage to 2032 in Europe and 2034 in the United States. Now, let me just address a question that comes up, and that’s the potential for biosimilar impact. And specifically, let me address what we see are several unique dynamics around the loss of rHuPH20 exclusivity. As a reminder, the base composition of patents for rHuPH20 lasts until 2024 in Europe and 2027 in the United States. Often with biotech products, with exclusivity loss there is going to be a sharp drop in revenue, sometimes referred to as a patent cliff. This is a result of biosimilar companies launching and taking a substantial share of the innovator product and also price erosion. We do not believe this will be the case with our enhanced portfolio considering the product composition and the projected IP coverage we have. Distinctly from the usual dynamics of $1 billion route with revenue potential is not based on a single product. It's based on more than 20 products. We also project and expect that multiple subcu products with ENHANZE will be protected with co-formulation patents. And companies contemplating ENHANZE for only a portion of the $1 billion may find it to be cost prohibitive and complex for limited reward. Further adding to our convictions regarding the durability of our royalty revenues, many of our partner products are patent protected beyond 2027. In addition, our partners have a strong focus on providing safe and reliable rHuPH20, also known as our API. With more than 600,000 patients now attributed to ENHANZE, we have a well characterized and established safety track record, including strong data regarding its effectiveness, a key question for new and potential partners. We are continuously improving our API and we’re now investing to create a next generation higher yield low-cost API. We believe our winning combination of high-quality API plus low cost will contribute to strong collaboration with our partners and durability of our revenues. Now, we're excited by the ongoing momentum and growth potential of our enhanced technology franchise. At the same time, we are continuing to evaluate the potential for new technology platform expansion through acquisition. Our goal with M&A is to advance our platform, but we see a clear path to operationalize that platform, just as we've done with ENHANZE, and deliver incremental value over and above the acquisition price. With that, I’m now going to turn the call over to Nicole for a discussion of our fourth quarter and full-year financial results.

Thank you, Helen. Before I begin, I would like to again note that we now report key measures on a non-GAAP basis in addition to the GAAP basis and also provide financial guidance on a non-GAAP basis. We consider these non-GAAP measures to be important because they provide useful measures of our operating performance. Excluding the factors that do not directly affect what we consider to be our core operating performance, such as stock-based compensation and amortization, as well as unusual events and their related tax effects. Please refer to our press release and filings for a reconciliation of GAAP to non-GAAP net income and earnings per share. With that, let me turn to Slide 9, where I’ll focus on some highlights from our fourth quarter results. Royalty revenue for the quarter was $62.6 million, a 96% increase over the prior year period of $32 million. This was driven primarily by the continued strong uptake of Janssen’s subcutaneous DARZALEX utilizing ENHANZE. Collaboration revenue for the fourth quarter was $12.3 million, as compared to $57.3 million in the prior year period. In Q4 2021, there were no new upfront license payments as compared to a $30 million upfront license payment from Horizon in Q4 2020. Lastly, GAAP EPS was $0.46 and non-GAAP EPS was $0.42 per diluted share. And now, let me turn to Slide 10 for a review of the full-year 2021 results. I'll briefly touch on some highlights here with more details available in our press release and 10-K filed with the SEC today. Total revenues grew 66% to $443.3 million in 2021, off of an already substantial revenue base in 2020. The biggest contributor to this increase was higher revenues from royalties of $203.9 million, up 130% from 2020. Product sales of $104.2 million were up sharply from $56 million, mainly due to higher sales of rHuPH20 to our partners Janssen and Roche. Collaborative revenues driven by our partners' pipeline progress were $135.2 million, up from $123 million in the prior year, benefiting from substantial sales milestones from Janssen related to DARZALEX SC in our new enhanced collaboration agreement with ViiV. Operating income for the full-year was $275.9 million, up 91% from $144.3 million in 2020. Earnings per share for 2021 reached the highest level in the company's history. GAAP EPS was $2.74, up from $0.91 in the prior year. As a reminder, GAAP EPS included a one-time tax benefit from the reversal of our tax valuation allowance, representing approximately $1.05 per share. Non-GAAP EPS for the year was $2 per share, up from $1.12 in the prior year. Now, let me turn to Slide 11 for a review of our 2022 financial guidance. I’m pleased to review our strong guidance for 2022, which was first introduced earlier this year. We expect total revenues of $530 million to $560 million, representing growth of 20% to 26% over 2021 total revenue. In terms of the components of our revenues, we expect revenue from royalties to increase approximately 50% over revenues from royalties in 2021 to approximately $300 million. Product sales and collaborative revenues in total for 2022 are expected to be at similar levels to what we achieved in 2021. We expect GAAP operating income of $350 million to $380 million, representing growth of 27% to 38% over 2021 GAAP operating income. This includes an incremental $20 million operating expense investment to maximize ENHANZE and extend royalty revenue durability. Even with this important investment, we expect operating margins greater than 65%. We expect GAAP diluted earnings per share of $1.90 to $2.05. Again, in 2021, we recorded a one-time non-cash income tax benefit of approximately $1.05 per share. When comparing with the prior year, it's important to note that 2022 will be the first fiscal year in which we will report income tax expense as part of our income statement. We expect non-GAAP diluted earnings per share of $2.05 to $2.20. Income tax expense is projected to be $0.55 to $0.60 per share. The company's earnings per share guidance does not consider the impact of potential future share repurchases beyond the accelerated share repurchase initiated in December of 2021. Let me now turn to Slide 12 for a summary of our approach to value creation and capital return and our strong progress to date. We have been consistent regarding our balanced capital allocation priorities. These include maintaining a strong balance sheet, capital return via share repurchases, and commitment to driving both internal and external growth via M&A. We have a strong balance sheet with cash, cash equivalents, and marketable securities as of the end of the fourth quarter of $740.9 million. We continue to expect our strong projected free cash flow driven by our enhanced franchise will support both our commitment to capital return as well as fund both internal and external growth via M&A. Demonstrating our continued commitment to capital return in the fourth quarter of 2021, we completed our initial three-year $550 million share buyback program, one year early. Under the program, which began in November 2019, we repurchased a total of 22.3 million shares for $550 million, at an average price per share of $24.71. Further demonstrating our commitment to capital return, in December 2021, we announced a new three-year $750 million share repurchase program that was authorized by our Board, and immediately initiated a $150 million accelerated share repurchase program. With that, I'll now turn the call back to Helen.

Thank you, Nicole. I'd like to thank the Halozyme team, our partners, and all of our collaborators for the hard work that resulted in the strong 2021 performance. In 2022, we'll continue to deliver growing revenues, growing operating income, and expanding our pipeline resulting in both strong near-term and long-term growth. I thank you for joining us today. And with that, we'd now be delighted to take your questions. Operator, would you please open the call for questions?

Thank you. We’ll go first to Charles Duncan from Cantor Fitzgerald.

Hey, thanks for taking the question and congratulations on a great year Helen and team. Thanks. Quick question, in terms of royalty growth, you mentioned the roughly 50% royalty growth this year, and I guess I'm kind of wondering if you could provide a little color on what the kind of puts and pulls to that royalty growth could be? Is that primarily driven by additional FASPRO growth or does Phesgo come into the picture? And then I guess as a follow-up to that, when you think about the 76% or so adoption rate for FASPRO versus DARZA IV, I guess, I’m wondering where do you think that can go?

Thanks, Charles. So, in terms of the royalty growth, the growth is driven by both FASPRO and by Phesgo. As we mentioned in the prepared remarks, we see growth for each of them. We call that FASPRO a bigger brand. It is going to be a larger contribution, but we're excited about the contribution we're going to see from Phesgo as well, which is going to come from additional launches outside the U.S. and more adoption in the U.S., which is a little bit behind, but also continued penetration into accounts in the U.S. as well. So, those are our two key royalty growth drivers. Specific to DARZALEX, while the exit as we saw was 76%, our average share in the year was just 58%. And so, we did think about the key drivers of our royalty revenue growth. First of all, we’ve got a very fast-growing brand in DARZALEX, at $6 billion in 2021, but analysts are projecting it's going to $10 billion by 2025. So, if you like the whole pie is going to get bigger. Our share will grow from the average share of 58% considerably above that. I think a good benchmark is, it's already at 76% at the end of last year. We're going to see more area under the curve sales as we continue to grow even catching up to that average of 76%, and frankly, there are very few barriers I think that would keep patients from using subcutaneous over IV given the potential for reduced treatment time and also reduced infusion-related reactions. So, we see a lot of growth to come.

Okay. Very good. One quick pipeline question, and that is on Efgartigimod, you mentioned possible data here in the near-term as guided by your partner? And I guess I'm wondering if you could provide a little bit of an outline on the work that you're doing to prepare for regulatory approval. I said that would be a new partner that you'd support in those efforts?

Yes, good question. So, if you're mentioning the data readout sometime in the first quarter, there is a study that's going to read out regarding their Phase 3 study, which is measuring reduction in IgG levels at day 29. Argenx has also stated that they are waiting on additional data that come from longer-term studies to complete their package. So, we are following our normal process Charles. We will be ready with all of the sections that are needed, related specifically to our drug products. With our five approvals to date, we’ve become very proficient and quick at doing that. Everything is very nicely on track to support Argenx when they are ready to submit their BLA.

Up next we’ll take a question from Michael DiFiore, Evercore ISI.

Hi guys. Thanks for taking my question and congrats on the great quarter and a phenomenal year. Just two for me, if I may. Number one, just regarding your next-gen higher yield low-cost API, I know you said you just started investing behind that, when can we expect this to become available? And the second part to that is, does this have any unique IP that may push out the 2024/2027 dates? And as a follow-up, on Slide 6, I’m not sure if I'm missing something, but I noticed that ALXN1720 and Bristol 73 are no longer on that chart, any color as to what happened would be great? Thank you.

Yes, so let me begin with the next generation high-yield low-cost API. We have just very recently begun investing in that Mike. So, we're still in the process of development and optimization. We don't have a specific timeline yet of when it will be introduced, but we are working as fast as we can to have that ready, but think in terms of several years to have that fully scaled up, tested, and stability checked, and all the other things that we need to do. So, several years from that point. It does not have unique IP associated with it because it is ENHANZE. Now, you will recall that in January, we also announced the development of a new rHuPH20, which is not enhanced. That one does have unique IP associated with it, extending through 2032 in Europe and 2034 in the United States. So, let me move then to your question about the pipeline. Yes, you’re absolutely correct. Let me start with PD-73; very recently, BMS, based on the overall data they have been seeing on the drugs that are addressing that target with IV indicated to us they wouldn't be proceeding with the development of that product as a subcutaneous formulation. And so, we did remove it from our pipeline chart. Moreover, they have communicated to us that they would not be continuing with the C5 target and they actually returned that target to us. So, there are always some puts and takes in the pipeline that we’re obviously excited to see the six new products starting in 2021, but we did see these programs for different reasons drop from development; in the case of PD-73, it just doesn't seem to be that attractive as a target in immune-oncology.

Got it. Thank you very much.

Up next we’ll hear from Corinne Jenkins, Goldman Sachs.

Hey, good afternoon. Moving first just one, you announced obviously this new rHuPH20 back in January, and I'm curious if the news of that product has shaped if at all your conversations with potential partners or even existing partners thinking about new product targets and partnerships?

Yes. Thanks, Corinne. Absolutely. We're still in the process of rolling out and getting into deeper conversations with all of our current partners. I can say that we're seeing some interest in that concept, and there are two areas that we’ve discussed where we’re seeing that interest. Partners who are considering developing small molecules may find our more extended room temperature stability attractive. Also, current partners who are developing drugs where they are more interested in a longer IP perhaps because their own product does not have as extended IP. So, we are very much engaging our current partners in discussions about this and we're beginning to introduce it in our new partner discussions as well, because we’ve seen certainly since the announcement of the new extended room temperature stable product more interest from companies who are pursuing small molecules, which is a great additional offering to discuss with them.

Thank you. And then maybe, I'm not sure if you have the visibility, but in terms of what percentages total are sales are FASPRO, I'm curious if you have any color on what's trending?

Unfortunately, Janssen doesn't provide that level of detail. So, we're not in a position to be able to share that. I can say though and we can go back to comments that Janssen made in June or July of last year. At that point in time, they were saying, ex-U.S. The FASPRO conversion was 60%. They have since seen its conversion increase considerably from that 60% reported, but we can't provide specific details.

Next up is Jessica Fye, JP Morgan.

Hey guys good afternoon, and thanks for taking my question. Just following up on some of the prior questions for the rHuPH20 with extended room temperature stability and potential for patient self-administration, when should we expect that to enter the clinic? And can you just talk about the type of product that would most benefit from those characteristics?

Yes. With the new rHuPH20, we are still in the process of, obviously, developing it and optimizing it. We expect that to be available to partners to integrate into their clinical program in a couple of years. From there, these partners need to conduct Phase 1 and Phase 3 studies just like with ENHANZE. So, we're estimating this could be available for first potential launch post-2027, with the same expedited development pathway we see with ENHANZE just a couple of years after it is ready and we have the right stability and information for partners to integrate into their clinical development programs. As you're thinking about the types of products that it might be useful for, I don't want to name a specific product, but these would be conditions where it may be more convenient for patients to carry around a self-injector or pre-filled syringe that has the drug because it’s for chronic use, but where they may want to have it with them and not have their life impacted by having to be tied to home. That's the type of situation where we're seeing partners be very interested in extended room temperature stability.

Okay. Got it. And maybe just one more from me, for the long-term royalty revenue potential where you're now providing an indication of what that could look like in 2031, going out beyond the 2027 figure that you've been giving for a while, how did you select 2031 as the kind of out year to provide there?

We’ve elected to show what would happen because there was so much focus on 2027, we just selected something to show pretty close to that, but several years out what the dynamic would be. Obviously, we could have picked one-year before, one-year after, but it just was picked to address that there is strong growth potential for several years after 2027.

Our next question comes from Jason Butler with JMP Securities.

Hi, thanks for taking the questions. Just a couple on the pipeline. I'm just – one on TAK-881, can you maybe just speak to how that product could fit into the overall IVIG franchise for Takeda and specifically how a 20% subcutaneous formulation could potentially – how the market dynamics could play out there for a subcutaneous conversion versus how they played out with HYQVIA? And then just real quick, could you remind us on the Phase 3 timelines to these Nivolumab and your thoughts on how that product will impact the PD-1 market? Thanks.

All right. Regarding the IVIG market and exactly what Takeda is planning, they have not shared their specific plans and positioning for this new agent publicly. I do see this as an additional offering for them in what is a very strong franchise and one that they have commented is one of their key growth drivers moving forward, but I can't comment on any specific positioning there. For the Nivolumab Phase 3 study, that continues to be executed by Bristol. They haven't provided any specific timeline. I can’t comment that on clinicaltrials.gov; they have a primary completion date of December of 2023, which is sometimes a useful indicator as to when they expect perhaps the first analysis to be done, but clearly that might not always hold true. Bristol believes subcutaneous therapy will allow patients to be treated more in the community and with more ease, and obviously in Bristol’s case, a combination of different checkpoint inhibitors to reduce the burden for the patient and also for the caregiver. So, we're very excited to see the progress they're making and remember they also have a Phase 1 study ongoing with appeal and relatlimab, which I think is going to be a very interesting combination as well.

Next up from Berenberg Capital Markets is Anita Dushyanth. Anita, your line is open.

Hi, can you hear me?

Yes, ma'am. Please go ahead.

We can now hear you, Anita. Thank you.

All right. Thanks. I had a quick question on Slide 6, a comment about the expected candidates to enter the pipeline, to say four new products, now would that mean that they have an IV version that’s already in the market or will those be brand new, like new molecules that the partners have seen in a subcutaneous formulation? And as a follow-up also, if the comment is five new Phase 2 trials, would you be able to give us some specifics on which of those Phase I might progress in the development? Thank you.

Hi. Thanks for the question, Anita. If we go to that chart in the specific studies that started in the fourth quarter, I can’t say that Cabotegravir, which is Janssen’s drug, is available as an oral and an IM formulation, including the use of it for combination therapy with the recently updated label to every two months. So that one is a commercialized drug. We cannot comment on the Roche product because obviously they have not disclosed their plans yet. The Takeda one is the 20% IgG, that is a developmental drug and then Cabotegravir at HIV drug as we've mentioned is approved. Just then moving to your second question with regard to the pipeline, we're very pleased, you probably have noticed on the chart that we are indicating that Roche is close to initiating their Phase 3 study for the projektnummer drug, and the trial design is published now on clinicaltrials.gov. This is one of the expected Phase 2 trials that will start. The remaining 4 will come from products that are on this chart, but unfortunately, based on the confidentiality agreements we have in place until the product has been announced, we cannot comment on it. The good news is, these will all be studies done in patients, and so shortly before the start, it will be posted on clinicaltrials.gov to provide updates as soon as we can about which these products are.

Thank you. That's very helpful. And just one more question for me. You did talk about looking into some of the potential acquisitions that could happen down the year. Maybe could you provide some color on what that implies when you say, you're looking at de-risked assets, whether they would be late stage or maybe close to approval or already approved?

Yes, thanks. As we are looking at some M&A, we're specifically looking to find a business that is complementary to ENHANZE and we're looking for something where we have confidence that we're going to be able to deliver value because we can operationalize it over and above what we would pay for it. What is ideal is that we can find something that already is being licensed to partners and has demonstrated some clinical or commercial success, or it is a pipeline that's got positive Phase 3 data and a clear path to regulatory approval. We don’t want to get into some pipeline where there is a lot of technical risk still because that obviously doesn't fit our goal of acquiring something to continue to build and extend the durability of our revenue. So, to fit our revenue and financial goals, it needs to be more advanced and that's what we mean by de-risking; we see a clear path to revenue and revenue growth in the near-term.

Our next question will come from Joe Catanzaro, Piper Sandler.

Hey, guys thanks so much for taking my questions and congrats on the progress. I just wanted to follow-up on an earlier question. Helen, I think you noted that for CD-73 maybe as a target, it just didn't meet Bristol’s expectations, but can you say what the sort of contributing factors were that led to that target being returned back to you guys? And maybe similarly, I think, amivantamab was in the enhanced pipeline earlier last year and then subsequently came out, what drove that decision? Those two questions, maybe you could just speak at a high level of what you're seeing within ENHANZE by specific molecules?

Yes, for ALXN1720, I’m afraid I don't have any color specifically on why they returned the target, but we can see that obviously, Alexion has had amazing success with ULTOMIRIS and the more extended IV dosing interval. In the previous years, they have made comments to say that the IV was a little bit surprising to them in that particular patient setting, but we don’t have any more color I can provide than that. The great news is, we're now in a position to relicense that target potentially to somebody else as there are a number of companies developing exciting products in that space. So, we will be seeking to do that as soon as possible. Regarding amivantamab, we are continuing in development with amivantamab with Janssen. They have a specific preference as to how and where we articulate that we're proceeding with amivantamab. So, you'll find more details on that in our quarterly report, which is an SEC filing, but based on Janssen’s preference, it is not reflected as clearly on our Halozyme chart that we use for investor meetings, but just to put a very fine point on it, absolutely Janssen is continuing with amivantamab as the target for subcutaneous development. Operator, is there any more questions?

There are no further questions at this time. Would you like to make any closing remarks?

Yes. Just like to thank everybody for your attention. Obviously, a great year in 2021 we're set up for continued strong progress and growth in 2022 as well. We look forward to updating you on our next quarterly call. Thank you so much and good night.

And once again, ladies and gentlemen, that does conclude today's conference. We would like to thank you all for your participation. You may now disconnect.